New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
07:09 EDTGSKGlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Reports Q2 turnover down 4% to GBP5.56B. GSK said Pharmaceutical and Vaccines sales were down 4% primarily due to continued increased competition in U.S. respiratory market and generic competition to Lovaza. It added, "With declining Advair sales, new sales growth expected from Breo, Anoro and Incruse, together with anticipated anticipated products. Expect to maintain respiratory leadership position well into next decade."
News For GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information
December 5, 2014
06:04 EDTGSKGSK won't pursue divestment of certain brands in established products portfolio
As announced at the company’s Q2 results in July, GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.The company has evaluated all bids received and has concluded, consistent with its key criteria of maximizing shareholder value, not to pursue divestment of these products.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use